Related Experiment Video
Updated: Mar 23, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Immunotherapy for Non-Small Cell Lung Cancer - Finally a Hint of Hope
Gonzalo Recondo, Gonzalo Recondo, Fernando Galanternik
15170 U.S. Route 60 East, Huntington, WV 25705, USA. meval78@yahoo.com.
Abstract:
Lung cancer is a major public health problem worldwide and the leading cause of cancerrelated mortality in developed countries. Significant advances have been made especially with the discovery of targeted agents. However, only a small proportion of patients carry activating mutations; until recently conventional chemotherapy and angiogenesis inhibitors were the preferred treatment for the vast majority of patients. Now, the successful experience of anti-PD-1 agents may have opened the door to a novel and previously unexplored dimension in the treatment of lung cancer: immunotherapy. In this mini-review we will discuss the current applications and future consequences related this topic, paying special attention to the clinical studies that constitute the scientific evidence to supports its use.
Insights
Lung cancer immunotherapy, particularly anti-programmed death-1 (PD-1) agents, offers a new treatment dimension. This review covers current applications and future implications based on clinical evidence.
Area of Science:
- Oncology
- Immunology
- Public Health
Background:
- Lung cancer is a leading global cause of cancer mortality.
- Targeted therapies have advanced treatment, but benefit only a subset of patients.
- Conventional chemotherapy and angiogenesis inhibitors were standard for most patients.
Purpose of the Study:
- To review the current applications of anti-PD-1 agents in lung cancer treatment.
- To explore the future implications of immunotherapy in lung cancer care.
- To highlight clinical studies supporting the use of immunotherapy.
Main Methods:
- Mini-review of existing literature.
- Focus on clinical studies and scientific evidence.
- Discussion of anti-PD-1 agents and immunotherapy.
Main Results:
- Immunotherapy, specifically anti-PD-1 agents, represents a significant advancement.
- Clinical studies provide evidence for the efficacy of these novel treatments.
- A paradigm shift in lung cancer treatment is occurring.
Conclusions:
- Anti-PD-1 agents have opened a new era in lung cancer treatment.
- Immunotherapy is a promising frontier with substantial clinical evidence.
- Further research and application of immunotherapy are expected.
More Related Videos
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...